The Ritedose Corporation, a South Carolina-based pharmaceutical manufacturer specialising in Blow-Fill-Seal (BFS) technology, on Wednesday unveiled its new distribution and logistics facility at Performance Park.
At the heart of Performance Park is a new 225,000-square-foot central distribution and logistics centre that is claimed to expand Ritedose's capabilities to handle well over 2 billion doses per year. The new facility is part of a multiphase USD81m investment that has created an additional 100 new jobs.
"This purpose-built facility marks the next phase of growth for Ritedose Performance Park," said Ritedose CEO Jody Chastain. "It expands our capabilities to handle logistics and distributions of well over 2 billion doses per year. However, we weren't just thinking about growing square footage, labs or equipment when we started planning this facility -- our thoughts were also on growing our people and supporting our community. We're a different kind of company that is deeply rooted in our purpose and driven by passion to make a difference in the lives of others, and we're just getting started."
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA